DCPH Overview

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Wall Street analysts forecast DCPH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Deciphera Pharmaceuticals Inc revenue for the last quarter amounts to 45.00M USD, increased 34.55 % YoY.

Deciphera Pharmaceuticals Inc. EPS for the last quarter amounts to -0.52 USD, decreased -13.33 % YoY.

Deciphera Pharmaceuticals Inc (DCPH) has 355 emplpoyees as of January 24 2026.

Today DCPH has the market capitalization of 2.00B USD.